| Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal D Tamborero, R Dienstmann, MH Rachid, J Boekel, R Baird, I Braña, ... Nature Medicine 26 (7), 992-994, 2020 | 66 | 2020 |
| Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? M Moschetta, S Boussios, E Rassy, EP Samartzis, G Funingana, ... Annals of Translational Medicine 8 (24), 2020 | 41 | 2020 |
| Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer L Beer, P Martin-Gonzalez, M Delgado-Ortet, M Reinius, L Rundo, ... European radiology 31, 3765-3772, 2021 | 21 | 2021 |
| Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer J Spicer, B Basu, A Montes, U Banerji, R Kristeleit, GJ Veal, C Corrigan, ... Cancer Research 80 (16_Supplement), CT141-CT141, 2020 | 21 | 2020 |
| Clinically interpretable radiomics-based prediction of histopathologic response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma L Rundo, L Beer, L Escudero Sanchez, M Crispin-Ortuzar, M Reinius, ... Frontiers in oncology 12, 868265, 2022 | 17 | 2022 |
| Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer FC Martins, DL Couturier, I De Santiago, CM Sauer, M Vias, M Angelova, ... Nature Communications 13 (1), 6360, 2022 | 15 | 2022 |
| Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? IG Funingana, MAV Reinius, A Petrillo, JE Ang, JD Brenton Seminars in Cancer Biology 77, 67-82, 2021 | 12 | 2021 |
| An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions KNMJF Melek Akay, Ionut-Gabriel Funingana, Grisma Patel, Rami Mustapha ... Oncology and Therapy, 2021 | 11 | 2021 |
| The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma P Smith, T Bradley, LM Gavarró, T Goranova, DP Ennis, HB Mirza, ... nature communications 14 (1), 4387, 2023 | 9 | 2023 |
| A very rare presentation of lung cancer: Metastases to the distal phalanx of index–case report VA Afrasânie, AM Adavidoaiei, IH Zamisnicu, IG Funingana, MV Marinca, ... Medicine 98 (49), e17892, 2019 | 8 | 2019 |
| Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial J Spicer, B Basu, A Montes, U Banerji, R Kristeleit, R Miller, GJ Veal, ... Nature Communications 14 (1), 4180, 2023 | 5 | 2023 |
| Radiomic and volumetric measurements as clinical trial Endpoints—a comprehensive review IG Funingana, P Piyatissa, M Reinius, C McCague, B Basu, E Sala Cancers 14 (20), 5076, 2022 | 5 | 2022 |
| A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade … S Banerjee, V Michalarea, JE Ang, A Ingles Garces, A Biondo, ... Clinical Cancer Research 28 (21), 4634-4641, 2022 | 4 | 2022 |
| Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors IG Funingana, JS Bedia, YW Huang, A Delgado Gonzalez, K Donoso, ... Seminars in Immunopathology 45 (1), 43-59, 2023 | 3 | 2023 |
| 7P Integration of whole genome sequencing (WGS) into NHS pathways for high-grade ovarian cancer (HGOC): A single-centre prospective experience IG Funingana, J Trotman, J Ambrose, T Roberts, J Watkins, M Ridley, ... ESMO Open 8 (1), 2023 | 1 | 2023 |
| The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study PS Smith, T Bradley, LM Gavarró, T Goranova, D Ennis, H Mirza, ... medRxiv, 2022.10. 21.22280992, 2022 | 1 | 2022 |
| A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in … T Barrett, S Pacey, K Leonard, J Wulff, IG Funingana, V Gnanapragasam European Urology Open Science 38, 17-24, 2022 | 1 | 2022 |
| A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian … SN Banerjee, A Ingles Russo, A Biondo, IG Funingana, M Little, T Prout, ... Journal of Clinical Oncology 38 (15_suppl), 6043-6043, 2020 | 1 | 2020 |
| The ALK project: a real-world national network and database F Gomes, K Yip, N Tokaca, A Greystoke, C Escriu, J Conibear, S Ghosh, ... Lung Cancer 127, S31-S32, 2019 | 1 | 2019 |
| A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms N Zareian, O Eremin, H Pandha, R Baird, V Kwatra, G Funingana, ... Frontiers Media SA, 2024 | | 2024 |
